Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
Race to Erase MS Forum and Expo
Copolymer 1 inhibits manifestations of graft rejection.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
Clinical profile of malay children with optic neuritis.
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.

Pages